Clinical trials: psoriasis
Arthritis, Psoriatic
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by…
- Trial name
- SOLSTICE (NCT04936308)
- Testing
- Guselkumab
- Where
- 169 sites in United States, Argentina and 12 more
- Volunteers
- 453 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis
This study was conducted to evaluate the safety and tolerability of BOS-475 following single and repeat topical administration to healthy participants (Part A), and to evaluate the safety and tolerability of 42-day repeat topical…
- Trial name
- NCT03960450
- Testing
- BOS-475, Vehicle
- Where
- 3 sites in Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boston Pharmaceuticals
Plaque Psoriasis
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06973291
- Testing
- Zasocitinib, Deucravacitinib
- Where
- 113 sites in United States, Bulgaria and 6 more
- Volunteers
- 606 people
- Sponsor
- Takeda
Psoriasis
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis
This study will examine the safety and efficacy in subjects with moderate to severe psoriasis, as measured by Psoriasis Area and Severity Index(PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI) and other…
- Trial name
- NCT01837420
- Testing
- VB-201 80mg, VB-201 160mg
- Where
- 4 sites in Germany, Israel and 2 more
- Volunteers
- 194 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Psoriasis Vulgaris
Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules
In an early clinical research, 138 patients completed the treatment of Psoriasis Vulgaris by Acitretin Capsules in 8 weeks, the results indicate 75 cases effectively (54.3%), 50 cases invalid(36.2%), 13 cases serious(9.4%).
- Trial name
- NCT02715960
- Testing
- Acitretin Capsules
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Central South University
Psoriasis
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) =…
- Trial name
- GUIDE (NCT03818035)
- Testing
- Guselkumab
- Where
- 90 sites in France, Germany
- Volunteers
- 880 people
- Sponsor
- Janssen-Cilag International NV
Acne, Atopic Dermatitis
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.
- Conditions
- Acne, Atopic Dermatitis, Chronic Hand Eczema, Hidradenitis Suppurativa
- Trial name
- NCT05994976
- Testing
- Blood samples collection, Oral samples collection, Hair samples collection
- Where
- Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Innovaderm Research Inc.
Arthritis, Psoriatic
A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium
The study will include a representative sample of 150 patients with active Psoriatic Arthritis (PsA) for whom the treating rheumatologist has decided to begin treatment with apremilast.
- Trial name
- APOLO (NCT03096990)
- Testing
- apremilast
- Where
- 22 sites in Belgium
- Volunteers
- 106 people
- Sponsor
- Amgen
Plaque Psoriasis
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis.
- Trial name
- NCT07326813
- Testing
- D-2570 Tablet, BMS-986165 Tablet
- Where
- China
- Volunteers
- 477 people
- Sponsor
- InventisBio Co., Ltd
Psoriasis Vulgaris
LEO 90100 in the Treatment of Psoriasis Vulgaris
The purpose of this study is to investigate whether LEO 90100, calcipotriol and betamethasone are effective in the treatment of psoriasis vulgaris.
- Trial name
- NCT01536938
- Testing
- LEO 90100, Calcipotriol, Betamethasone
- Where
- 33 sites in United States
- Volunteers
- 303 people
- Sponsor
- LEO Pharma
Nail Psoriasis, Nail Damage
Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis
A randomized, double blind, placebo-controlled, unicenter, parallel group study to assess the efficacy, safety and tolerability of a multi-funtion toe nail patch in patients affected by nail fragility, nail mychosis and psoriasis…
- Conditions
- Nail Psoriasis, Nail Damage, Mycosis
- Trial name
- NCT07029516
- Testing
- Cosmetic patch containing urea applicated daily for 3 months
- Where
- Italy
- Volunteers
- 72 people
- Sponsor
- Wooshin Labottach Co., Ltd.
Psoriasis
Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.
Severe psoriasis has been demonstrated to be associated with decreased endothelial function and an increase risk of future coronary events.
- Trial name
- NCT01320293
- Testing
- Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of North Carolina, Chapel Hill
Plaque Psoriasis
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
The primary objective of this study is to determine the efficacy and safety of 074-6751 Lotion applied twice daily for four weeks (28 days) in clinical subjects with moderate plaque psoriasis.
- Trial name
- NCT03167515
- Testing
- 074-6751 Lotion
- Where
- 5 sites in United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Ferndale Laboratories, Inc.
Psoriasis
Curcuminoids for the Treatment of Chronic Psoriasis Vulgaris
Turmeric (Curcuma Longa) is member of the ginger family and is best known for its culinary use as the major of component of curry powder.
- Trial name
- NCT00235625
- Testing
- Curcuminoids C3 Complex®
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Pennsylvania
Psoriasis Vulgaris, Psoriasis
Modified Intermittent Fasting in Psoriasis
The complexity of psoriasis is partially affected by dietary effects, and some diets have shown to be beneficial in psoriasis. Intermittent fasting has been shown to improve many of these disturbances, even inflammatory…
- Trial name
- MANGO (NCT04418791)
- Testing
- Modified Intermittent Fasting followed by Regular Diet, Regular Diet followed by Modified Intermittent Fasting
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- University Hospital, Ghent
Psoriasis of Scalp
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis
The purpose of the study is to evaluate whether once daily topical treatment for up to 8 weeks of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) gel is safe and more effective than betamethasone 0.5 mg/g (as…
- Trial name
- NCT00216840
- Testing
- Calcipotriol plus betamethasone dipropionate (LEO80185 gel)
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 1,350 people
- Sponsor
- LEO Pharma
Psoriasis
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic…
- Trial name
- NCT03478787
- Testing
- risankizumab, secukinumab
- Where
- 61 sites in United States, Canada and 7 more
- Volunteers
- 327 people
- Sponsor
- AbbVie
Psoriatic Arthritis
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.
- Trial name
- NCT01925768
- Testing
- Apremilast 30 mg
- Where
- 71 sites in United States, Australia and 8 more
- Volunteers
- 219 people
- Sponsor
- Amgen
Psoriasis Vulgaris
To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%…
- Trial name
- NCT03731091
- Testing
- Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%, Enstilar® foam (LEO Pharma Inc.)
- Where
- 30 sites in United States
- Volunteers
- 494 people, healthy volunteers welcome
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Psoriasis Vulgaris
A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects
This is a phase 2, open-label, single-group, multicentre trial in which the investigational product, MC2-01 cream, is investigated in adolescent subjects (age 12 to 16 years, 11 months) with clinically diagnosed extensive…
- Trial name
- NCT03819218
- Testing
- MC2-01 cream
- Where
- 2 sites in Czechia, Germany
- Volunteers
- 7 people
- Sponsor
- MC2 Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.